Page last updated: 2024-11-11

sja 6017

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9885817
CHEMBL ID288365
SCHEMBL ID1907361
MeSH IDM0283336

Synonyms (21)

Synonym
sja 6017
sja-6017
calpain inhibitor vi
(2s)-2-[(4-fluorophenyl)sulfonylamino]-n-[(1s)-1-formyl-3-methyl-butyl]-3-methyl-butanamide
n-(4-fluorophenylsulfonyl)-l-valyl-l-leucinal
sja6017
CHEMBL288365 ,
(s)-2-(4-fluoro-benzenesulfonylamino)-n-((s)-1-formyl-3-methyl-butyl)-3-methyl-butyramide
(s)-2-(4-fluorophenylsulfonamido)-3-methyl-n-((s)-4-methyl-1-oxopentan-2-yl)butanamide
bdbm50114340
SCHEMBL1907361
190274-53-4
J-012283
calpain inhibitor vi - cas 190274-53-4
(s)-2-((4-fluorophenyl)sulfonamido)-3-methyl-n-((s)-4-methyl-1-oxopentan-2-yl)butanamide
butanamide, 2-[[(4-fluorophenyl)sulfonyl]amino]-n-[(1s)-1-formyl-3-methylbutyl]-3-methyl-, (2s)-
calpain-in-4
calpain inhibitor 4
CS-0077973
HY-118933
AKOS040749506

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"We previously reported a potent calpain inhibitor 1 (SJA6017, N-(4-fluorophenyl)-l-valyl-l-leucinal), which displayed relatively low oral bioavailability (BA)."( Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
Inoue, J; Miyashita, H; Nakamura, M; Sakai, O; Shirasaki, Y; Yamaguchi, M, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Calpain-9Homo sapiens (human)IC50 (µMol)2.23001.61003.97609.8800AID1620950
Calpain-1 catalytic subunitHomo sapiens (human)IC50 (µMol)0.02200.00021.059210.0000AID1812914; AID266803
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)20.00000.00022.45859.9600AID1845236
Calpain-1 catalytic subunitSus scrofa (pig)IC50 (µMol)0.02120.00751.52857.5000AID141773; AID339508
Calpain-2 catalytic subunitSus scrofa (pig)IC50 (µMol)0.07800.07800.08850.0990AID339511
Calpain-1 catalytic subunitRattus norvegicus (Norway rat)IC50 (µMol)0.00750.00750.00750.0075AID631286
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
digestionCalpain-9Homo sapiens (human)
proteolysisCalpain-9Homo sapiens (human)
proteolysisCalpain-1 catalytic subunitHomo sapiens (human)
positive regulation of cell population proliferationCalpain-1 catalytic subunitHomo sapiens (human)
regulation of macroautophagyCalpain-1 catalytic subunitHomo sapiens (human)
receptor catabolic processCalpain-1 catalytic subunitHomo sapiens (human)
regulation of catalytic activityCalpain-1 catalytic subunitHomo sapiens (human)
mammary gland involutionCalpain-1 catalytic subunitHomo sapiens (human)
self proteolysisCalpain-1 catalytic subunitHomo sapiens (human)
regulation of NMDA receptor activityCalpain-1 catalytic subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
calcium ion bindingCalpain-9Homo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-9Homo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-1 catalytic subunitHomo sapiens (human)
calcium ion bindingCalpain-1 catalytic subunitHomo sapiens (human)
protein bindingCalpain-1 catalytic subunitHomo sapiens (human)
peptidase activityCalpain-1 catalytic subunitHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
cellular_componentCalpain-9Homo sapiens (human)
cytoplasmCalpain-9Homo sapiens (human)
cornified envelopeCalpain-1 catalytic subunitHomo sapiens (human)
extracellular regionCalpain-1 catalytic subunitHomo sapiens (human)
mitochondrionCalpain-1 catalytic subunitHomo sapiens (human)
lysosomeCalpain-1 catalytic subunitHomo sapiens (human)
cytosolCalpain-1 catalytic subunitHomo sapiens (human)
plasma membraneCalpain-1 catalytic subunitHomo sapiens (human)
focal adhesionCalpain-1 catalytic subunitHomo sapiens (human)
membraneCalpain-1 catalytic subunitHomo sapiens (human)
extracellular exosomeCalpain-1 catalytic subunitHomo sapiens (human)
calpain complexCalpain-1 catalytic subunitHomo sapiens (human)
ficolin-1-rich granule lumenCalpain-1 catalytic subunitHomo sapiens (human)
cytoplasmCalpain-1 catalytic subunitHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID266803Inhibition of human erythrocyte mu calpain2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID339511Inhibition of pig CAPN22008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors.
AID631288Inhibition of ovine CAPN1 using BODIPY-labeled casein substrate by fluorometric analysis2011Journal of medicinal chemistry, Nov-10, Volume: 54, Issue:21
Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis.
AID266809AUC (0-infinity) in Sprague-Dawley rat at 3 mg/kg, iv2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID22002Water solubility was determined at pH 72002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Exploration of peptidyl hydrazones as water-soluble calpain inhibitors.
AID631286Inhibition of rat CAPN1 using BODIPY-labeled casein substrate by fluorometric analysis2011Journal of medicinal chemistry, Nov-10, Volume: 54, Issue:21
Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis.
AID266817Volume of distribution in Sprague-Dawley rat at 3 mg/kg, iv2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266806Metabolic stability in human hepatic S9 fraction after 0.5 hrs2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID141773Tested for inhibitory activity against porcine erythrocyte Mu-calpain2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Exploration of peptidyl hydrazones as water-soluble calpain inhibitors.
AID266816Terminal half life in Sprague-Dawley rat at 3 mg/kg, iv2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266804Inhibition of porcein kidney m calpain2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266818Clearance in Sprague-Dawley rat at 3 mg/kg, iv2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266807Apparent permeability from apical to basolateral side of the Caco-2 cell2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID1812914Inhibition of human Calpain-1 incubated for 60 mins by Bio-Rad protein assay dye reagent based assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.
AID266819Oral bioavailability in Sprague-Dawley rat2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266822Neuroprotective activity in Sprague-Dawley rat ischemia-reperfusion model measured as cell density in retinal ganglion cell layer at 500 mg/kg, po2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266815Tmax in Sprague-Dawley rat at 500 mg/kg, po2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID21997Water solubility was determined at pH 42002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Exploration of peptidyl hydrazones as water-soluble calpain inhibitors.
AID22000Water solubility was determined at pH 62002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Exploration of peptidyl hydrazones as water-soluble calpain inhibitors.
AID266811AUC (0-infinity) in Sprague-Dawley rat at 500 mg/kg, po2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266813Cmax in Sprague-Dawley rat at 500 mg/kg, po2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID1845236Inhibition of SARS-CoV-2 MPro2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID339508Inhibition of pig CAPN12008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors.
AID266805Aqueous solubility at pH 7 at 25 degreeC2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID266808Lipophilicity, log D of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
AID21999Water solubility was determined at pH 5; ND=Not determined2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Exploration of peptidyl hydrazones as water-soluble calpain inhibitors.
AID631289Inhibition of ovine CAPN2 using BODIPY-labeled casein substrate by fluorometric analysis2011Journal of medicinal chemistry, Nov-10, Volume: 54, Issue:21
Molecular modeling: a search for a calpain inhibitor as a new treatment for cataractogenesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.00)18.2507
2000's20 (80.00)29.6817
2010's1 (4.00)24.3611
2020's3 (12.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (96.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]